The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. (Q45420047)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Samuel Litwin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Eugene Toll

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

William S Mason

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

1 reference

1 December 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Virology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

34 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

S96-S107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Mutation rate of the hepadnavirus genome

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Detection of hepatitis b virus dna sequences in infected hepatocytes by in situ cytohybridisation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

A duck hepatitis B virus strain with a knockout mutation in the putative X ORF shows similar infectivity and in vivo growth characteristics to wild-type virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Frequency of spontaneous mutations in an avian hepadnavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Low dynamic state of viral competition in a chronic avian hepadnavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980018-6

7 January 2021

10.1016/S1386-6532(05)80018-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16461233%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference